Microencapsulation: The future of oral immunotherapy?

BioDrugs

Volumn 9, Issue 4, 1998, Pages 261-270

  Litwin, Allen ^a   Flanagan, Michael ^a   Michael, J Gabriel ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PLACEBO; POLLEN ANTIGEN; POLLEN EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HUMAN; IMMUNOTHERAPY; MICROENCAPSULATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; POLLEN ALLERGY; PRIORITY JOURNAL; RAGWEED POLLEN; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION;

EID: 0031959518     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809040-00001     Document Type: Review

References (66)

1. Lowell FC, Franklin W. A 'double-blind' study of treatment with aqueous allergenic extracts in cases of allergic rhinitis. J Allergy 1963; 34: 165-82
2. Van Metre Jr TE, Marsh DG, Adkinson Jr NF, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988; 82: 1055-67
3. Hunt KJ, Sobotka AK, Amodio FJ, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299: 257-61
4. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51: 430-3
5. Cooke RA, Bernard JH, Hebald S, et al. Serologic evdence of immunity with coexisting sensitization in a type of human allergy (hayfever). J Exp Med 1935; 62: 733-50
6. Loveless MH. Immunological studies of pollinosis: IV. The relationship between thermostable antibody in the circulation and clinical immunity. J Immunol 1943; 47: 1765-809
7. Lichtenstein LM, Holtzman NA, Burnett LS. A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968; 101: 317-24
8. Lichtenstein LM, Norman PS, Winkenwerder WL. A single year of immunotherapy for ragweed hayfever: immunologic and clinical studies. Ann Intern Med 1971; 75: 663-71
9. Hedlin G, Silber G, Naclerio R, et al. Attenuation of allergen sensitivity early in the course of ragweed immunotherapy. J Allergy Clin Immunol 1989; 84: 390-9
10. Nakagawa T, Kozeki H, Katagiri S, et al. Changes of house dust mite-specific IgE, IgG and IgG subclass antibodies during immunotherapy in pitients with perennial rhinitis. Int Arch Allergy Appl Immunol 1987; 82: 95-9
11. AAAI Board of Directors. Measurement of specific and non-specific IgG4 levels as diagnostic and prognostic tests for clinical allergy. J Allergy Clin Immunol 1995; 95: 652-4
12. Peng Z, Naclerio RM, Norman Jr PS, et al. Quantitative IgE and IgG subclass responses during and after long-term ragweed immunotherapy. J Allergy Clin Immunol 1992; 89: 519-29
13. Daëron M, Malbec O, Latour S, et al. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995; 95: 577-85
14. Larsen GL, Wilson ML, Clark RAF, et al. The inflammatory reaction in the airways in an animal model of the late asthmatic response. Fed Proc 1982; 46: 105-2
15. Montefort S, Graziou C, Goulding D, et al. Bronchial biopsy evidence for leukocyte endothelial cell adhesion molecule 6 hours after oral allergen challenge of sensitized asthmatic airway. J Clin Invest 1994; 93: 1411-21
16. Patterson R, Grammer LC, Shaughnessy MA. Immunotherapy: parameters of assessment. J Allergy Clin Immunol 1983; 76: 394-7
17. Levy D, Osler A. Studies on the mechanism of hypersensitivity phenomena. XV. In vitro assays of reaginic activity in human sera: effect of therapeutic immunization on seasonal titer changes. J Immunol 1967; 99: 1068-77
18. Evan R, Pence H, Kaplan H, et al. The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest 1976; 57: 1378-85
19. Kuna V, Alam R, Kuzminska B, et al. The effect of preseasonal immunotherapy in the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol 1989; 83: 816-24
20. Prazansky JJ, Patterson R. Histamine release from leukocytes of hypersensitive individuals: II. Reduced sensitivity of leukocytes after injection therapy. J Allergy 1967; 39: 44-50
21. Pieukowski M, Norman PS, Lichtenstein L. Suppression of late-phase skin reactions by immunotherapy with ragweed extract. J Allergy Clin Immunol 1985; 76: 729-34
22. Creticos P, Adkinson Jr F, Kugey-Sobotka A, et al. Nasal challenge with ragweed in hayfever patients: effects of immunotherapy. J Clin Invest 1985; 76: 2247-53
23. Furin M, Norman P, Creticos P, et al. Immunotherapy decreases antigen-induced eosinophil migration into the nasal cavity. J Allergy Clin Immunol 1991; 88: 27-32
24. Otsuka H, Ohnishi M, Okuho K, et al. Changes in nasal metachromatic cell during allergen immunotherapy. Clin Exp Allergy 1991; 21: 115-9
25. Robinson D, Kay A. Role of Th1 and Th2 cells in human allergic disorders. Chem Immunol 1996; 63: 187-203
26. Romagnani S. Th1 and Th2 cells in human disease. Clin Immunol Immunopathol 1996; 80: 225-35
27. Secrist H, Clelen C, Wen Y, et al. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178: 2123
28. Jutel M, Pichler W, Skubic D, et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen stimulated T cell cultures. J Immunol 1995; 154: 4187-94
29. Mocci S, Loffman R. The mechanism of in vitro T helper cell tvpe 1 to T helper cell type 2 in highly polarized Leishmania major-specific T cell populations. J Immunol 1997; 158: 1559-64
30. Bellinghausen I, Metz G, Enk A, et al. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997; 27: 1131-9
31. Lockey R. Adverse reactions associated with skin testing and immunotherapy. Allergy Proc 1995; 16: 293-6
32. Patterson R, Suszko I, McIntire F. Polymerized ragweed antigen E. I. Preparation and immunologic studies. J Immunol 1973; 110: 1402-12
33. Marsh D, Lichtenstein L, Campbell D. Conversion of group I rye pollen allergen to 'allergenic' by mild formalin treatment. J Allergy 1969; 43: 179
34. Taudorf E. Oral immunotherapy of adults with allergic rhinoconjunctivitis: clinical effects in birch and grass pollinosis. Dan Med Bull 1992; 39: 542-59
35. Möller C, Dreborg S, Lanner Å, et al. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. Allergy 1986; 41: 271-9
36. Taudorf E, Laursen L, Lanner A, et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987; 80: 153-61
37. Taudorf E, Laursen L, Larren A, et al. Specific IgE, IgG, and IgA antibody response to oral immunotherapy in birch pollinosis. J Allergy Clin Immunol 1989; 83: 589-94
38. Creticos P, Naclerio R, Adkinson Jr N, et al. Efficacy, safety and kinetics of oral ragweed immunotherapy in the treatment of allergic seasonal rhinitis [abstract]. J Allergy Clin Immunol 1990; 85: 214
39. Giovane A, Bardare M, Passalacqua G, et al. A three year double blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in pediatric patients. Clin Exp Allergy 1994; 24: 53-9
40. Taudorf E, Weeke B. Orally administered grass pollen. Allergy 1983; 38: 561-4
41. Tandorf E, Laursen LC, Djuvup R, et al. Oral administration of grass pollen to hay fever patients. Allergy 1985; 40: 321-35
42. Van Niekerk CH, Wet JLD. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay-fever: a double-blind study. Clin Allergy 1987; 17: 507-13
43. Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral immunotherapy with standardized cat extract. J Allergy Clin Immunol 1994; 93: 61-7
44. Ferguson Jr T, Peters T, Reed R, et al. Immunoregulatory properties of antigenic fragments from bovine serum albumin. Cell Immunol 1983; 78: 1-11
45. Zhang Z, Apple RJ, Pesce A, et al. Peptic fragments of bovine serum albumin bind antigen-specific T suppressor cells from orally tolerized mice. Cell Immunol 1987; 104: 426-33
46. Pesce AJ, Freisheim JM, Litwin A, et al. Modulation of the immune response to allergens: phospholipase A degradation products suppress IgG and IgE response in mice. Int Arch Allergy Appl Immunol 1990; 2: 88-93
47. Jain SL, Michael JG. The influence of antigen digestion on orally induced immunity and tolerance. In: Mestecky J, et al., editors. Advances in mucosal immunology. Part B. New York: Plenum Press, 1995: 1245-50
48. Michael JG. The role of digestive enzymes in orally induced immune tolerance. Immunol Invest 1989; 18: 1049-54
49. Lyce N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986; 59: 301-8
50. Ogra P, Leibovitz E, Ng Z. Oral immunization and secretory immunity to viruses. Curr Top Microbiol Immunol 1989; 146: 73-81
51. Michalek SM, Childers NK, Katz J, et al. Liposomes as oral adjuvants. Curr Top Microbiol Immunol 1989; 146: 51
52. Eldridge JH, Staas JK, Meulbrock JA, et al. Controlled vaccine release in the gut-associated lymphoid tissues: I. Orally administered biodegradable microspheres target for Peyer's patches. J Control Rel 1991; 11: 205-14
53. O'Hagan DT. Microparticles as oral vaccines. In: O'Hagan DT, editor. Novel delivery systems for oral vaccines. Boca Raton (FL): CRC Press, 1994: 175-205
54. Flanagan MF, Wang C, Michael JG. Characterization of the immune response following the oral administration of modified antigen in an adjuvant-free system. J Immunol 1993; 150: 35
55. Flanagan M, Wang C, Litwin A, et al. Induction of an immune response in BDF1 mice by microencapsulated allergens following oral delivery. J Allergy Clin Immunol 1994; 93 (1 Pt 2): 252
56. Flanagan M, Jain S, Michael J. Breaking of oral tolerance by an encapsulated antigen. Ann NY Acad Sci 1995; 778: 373-5
57. Jain SL, Barone S, Flanagan MP, et al. Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen. Vaccine 1996; 14: 42-8
58. Jain SL, Barone S, Michael JG. Activation patterns of murine T cells after oral administration of an enterocoated soluble antigen. Cell Immunol 1996; 167: 170-5
59. Litwin A, Flanagan M, Entis G, et al. Immunologic effect of encapsulated short ragweed extract: a potent new agent for oral immunotherapy. Ann Allergy Asthma Immunol 1996; 77: 132-38
60. Creticos PS, Van Metre TE, Mardiney MR, et al. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984; 73: 94-104
61. Litwin A, Flanagan M, Entis G, et al. Oral immunotherapy with short ragweed extract employing a novel encapsulated preparation - a double blind study. J Allergy Clin Immunol 1997; 100: 30-8
62. Abu-Ghazaleh RI, Fujisawa T, Mestecky J, et al. IgA-induced eosinophil degradation. J Immunol 1989; 142: 2393-400
63. Van Deusen M, Angelini BL, Cordoro K, et al. Efficacy and safety of oral immunotherapy with short ragweed extract. Ann Allergy Asthma Immunol 1997; 78: 573-80
64. Franklin W, Lowell FC. Comparison of two dosages of ragweed extract in the treatment of pollenosis. JAMA 1967; 201: 915-17
65. Van Metre TE, Adkinson Jr NF, Amodio FJ, et al. A comparison of immunotherapy schedules for treatment of ragweed pollen hayfever. J Allergy Clin Immunol 1982; 69: 181-93
66. Stewart II GE, Lockey RF. Systemic reactions from allergen immunotherapy [editorial]. J Allergy Clin Immunol 1992; 90: 567-78